인간 마이크로바이옴 시장 : 질환별, 기술별, 제품별, 치료 영역별, 용도별 - 세계 예측(2025-2030년)

The Human Microbiome Market was valued at USD 1.58 billion in 2023, expected to reach USD 1.96 billion in 2024, and is projected to grow at a CAGR of 23.90%, to USD 7.11 billion by 2030.

The human microbiome refers to the vast consortium of microorganisms residing on and within the human body, encompassing bacteria, viruses, fungi, and other microbes. Its definition extends to a critical component of human health, influencing digestion, immunity, and even mental well-being. The necessity of exploring the human microbiome is driven by its potential to revolutionize health treatments and disease prevention. Applications span from personalized medicine to probiotics, reflecting diverse end-use arenas in healthcare, pharmaceuticals, and biotechnology industries. The market insights suggest robust growth fueled by increased research investment and consumer awareness of microbiome-related health benefits. Key influencing growth factors include technological advancements in genomic sequencing and growing collaborations between biotech firms and research institutions to develop innovative therapies. Opportunities are emerging rapidly, particularly in developing targeted probiotics and prebiotics, microbiome diagnostics, and therapeutic solutions for diseases like inflammatory bowel disease and diabetes. To capitalize on these, businesses should focus on dynamic partnerships and continuous R&D to drive microbiome-product integration into mainstream applications. However, limitations such as high development costs, regulatory challenges, and the complexity of understanding microbiome dynamics tempers growth. Privacy concerns regarding genomic data also pose barriers. Addressing these challenges requires transparent regulatory pathways and collaborations to enhance data accuracy and privacy protections. The best areas for innovation and research include synthetically engineered microbiomes for therapeutic purposes and advancing techniques in metagenomic analysis to better understand host-microbe interactions. The market is rapidly evolving, marked by a competitive yet collaborative nature as companies strive to harness microbiome data for improving health outcomes. Thus, firms should adopt a strategic approach combining robust research, regulatory awareness, and market diversification to achieve business growth in this promising domain.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Microbiome Market

The Human Microbiome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increased Focus on Development of Human Microbiome Therapy
  • Human Microbiome for Drug Discovery, Early Disease Detection, and Diagnosis
  • Increasing Demand for Microbiome in Probiotics and Infant Nutrition
• Market Restraints
  • Limited Expertise and Safety Issue related to Microbiome Therapeutics
• Market Opportunities
  • Increasing Collaborations and Research Investments to Create Growth Opportunities
  • Development of Novel Human Microbiome Therapeutic Products
• Market Challenges
  • Limitations in Understanding Number of Bacterial Species and Uncertainty of Human Microbiome-Based Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Human Microbiome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Microbiome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Microbiome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Microbiome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Microbiome Market

A detailed market share analysis in the Human Microbiome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Microbiome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Microbiome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Human Microbiome Market, highlighting leading vendors and their innovative profiles. These include Merck KGaA, Theriva Biologics, Inc., BiomeSense, Inc., Metabiomics Corporation, Exeliom Biosciences SAS, Ferring B.V., Evelo Biosciences, Inc., Locus Biosciences, Inc., Intralytix, Inc., Seres Therapeutics, Inc., DuPont de Nemours, Inc., Invivo Healthcare, Vedanta Biosciences, Inc., Astarte Medical Partners, Inc, Synlogic, Inc., Finch Therapeutics Group, Inc., Rebiotix Inc., Osel Inc., Second Genome, Inc., Enterome Bioscience, Axial Therapeutics, Inc., Viome Life Sciences, Inc., Yakult Honsha Co., Ltd., Azitra, Illumina, Inc., BiomX Ltd., and AOBiome, LLC.

Market Segmentation & Coverage

This research report categorizes the Human Microbiome Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease, market is studied across Acute Diarrhea, Autoimmune Disorders, Cancer, Diabetes, Mental Disorders, and Obesity.
• Based on Technology, market is studied across 16s rRNA Sequencing, Cell Culture Technology, Computational Tools, High-Throughput Technology, Metagenomic Sequencing, and Omics Technology.
• Based on Product, market is studied across Diagnostic Devices, Drugs, Foods, and Prebiotic & Probiotics.
• Based on Therapeutic Area, market is studied across Gastrointestinal Disorders, Metabolic Disorders, Skin Disorders, and Women's Health.
• Based on Application, market is studied across Diagnostics and Therapeutics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased Focus on Development of Human Microbiome Therapy
    • 5.1.1.2. Human Microbiome for Drug Discovery, Early Disease Detection, and Diagnosis
    • 5.1.1.3. Increasing Demand for Microbiome in Probiotics and Infant Nutrition
  • 5.1.2. Restraints
    • 5.1.2.1. Limited Expertise and Safety Issue related to Microbiome Therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing Collaborations and Research Investments to Create Growth Opportunities
    • 5.1.3.2. Development of Novel Human Microbiome Therapeutic Products
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations in Understanding Number of Bacterial Species and Uncertainty of Human Microbiome-Based Drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Recent advancements in 16s rRNA sequencing and omics technology to investigate molecular factors and processes in human body
  • 5.2.2. Application: The increasing adoption of the human microbiome in healthcare diagnostics and therapeutics to cater to various health conditions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization
  • 5.5.1. Intellectual Property Landscape

6. Human Microbiome Market, by Disease

• 6.1. Introduction
• 6.2. Acute Diarrhea
• 6.3. Autoimmune Disorders
• 6.4. Cancer
• 6.5. Diabetes
• 6.6. Mental Disorders
• 6.7. Obesity

7. Human Microbiome Market, by Technology

• 7.1. Introduction
• 7.2. 16s rRNA Sequencing
• 7.3. Cell Culture Technology
• 7.4. Computational Tools
• 7.5. High-Throughput Technology
• 7.6. Metagenomic Sequencing
• 7.7. Omics Technology

8. Human Microbiome Market, by Product

• 8.1. Introduction
• 8.2. Diagnostic Devices
• 8.3. Drugs
• 8.4. Foods
• 8.5. Prebiotic & Probiotics

9. Human Microbiome Market, by Therapeutic Area

• 9.1. Introduction
• 9.2. Gastrointestinal Disorders
• 9.3. Metabolic Disorders
• 9.4. Skin Disorders
• 9.5. Women's Health

10. Human Microbiome Market, by Application

• 10.1. Introduction
• 10.2. Diagnostics
• 10.3. Therapeutics

11. Americas Human Microbiome Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Human Microbiome Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Human Microbiome Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Clinical Microbiomics Announces Merger with CosmosID
  • 14.3.2. Nestle Partners APC Microbiome on Health and Wellbeing Products
  • 14.3.3. UW Medicine Launches a New Center to Study Microbiomes

Companies Mentioned

• 1. Merck KGaA
• 2. Theriva Biologics, Inc.
• 3. BiomeSense, Inc.
• 4. Metabiomics Corporation
• 5. Exeliom Biosciences SAS
• 6. Ferring B.V.
• 7. Evelo Biosciences, Inc.
• 8. Locus Biosciences, Inc.
• 9. Intralytix, Inc.
• 10. Seres Therapeutics, Inc.
• 11. DuPont de Nemours, Inc.
• 12. Invivo Healthcare
• 13. Vedanta Biosciences, Inc.
• 14. Astarte Medical Partners, Inc
• 15. Synlogic, Inc.
• 16. Finch Therapeutics Group, Inc.
• 17. Rebiotix Inc.
• 18. Osel Inc.
• 19. Second Genome, Inc.
• 20. Enterome Bioscience
• 21. Axial Therapeutics, Inc.
• 22. Viome Life Sciences, Inc.
• 23. Yakult Honsha Co., Ltd.
• 24. Azitra
• 25. Illumina, Inc.
• 26. BiomX Ltd.
• 27. AOBiome, LLC